Introduction
The muscarinic cholinergic family of G protein-coupled receptors includes five muscarinic receptor subtypes designated M 1 to M 5 (1) (2) (3) . M 3 muscarinic receptors (M 3 R), expressed widely in the gastrointestinal tract, couple to G q11 , activate phospholipase C signaling and inositol phosphate formation, and increase cell calcium, thereby altering cell function, including proliferation (4) . In 1991, Gutkind et al. (5) reported that muscarinic receptors linked to phosphatidylinositol hydrolysis (i.e., M 1 R, M 3 R, and M 5 R) act as conditional oncogenes when expressed in cells capable of proliferation. Subsequently, Frucht and colleagues (6, 7) reported that human colon cancer cell lines and colon cancer tissue express M 3 R, and that M 3 R expression was increased up to 8-fold in cancer compared with normal tissue. Collectively, these findings suggest that the M 3 R is an important player in colon neoplasia.
Work from our laboratory elucidated cellular mechanisms underlying acetylcholine-induced colon cancer cell proliferation. In H508 human colon cancer cells that express high levels of M 3 R (8), acetylcholine activates postreceptor signaling, including robust phosphorylation of extracellular signal-regulated kinase (ERK)1/2 and p90 RSK , a nuclear response protein that regulates gene expression and the cell cycle (9) . These actions of acetylcholine are blocked by muscarinic receptor inverse agonists, calcium chelators, and inhibitors of mitogen-activated protein/ERK kinase (the regulatory protein just upstream of ERK), and they do not occur in SNU-C4 human colon cancer cells that do not express M 3 R (9). Moreover, recent studies support the hypothesis that luminal bile acids, long associated with the development of colon cancer (10), also stimulate colon cancer cell proliferation by M 3 R-and epidermal growth factor receptor-dependent mechanisms (11) (12) (13) . In these in vitro cell systems, proliferative actions of muscarinic agonists require both M 3 R expression and activation of post-M 3 R signaling.
Given the key role of M 3 R expression in proliferation of human colon cancer cells, it is important to determine whether genetic ablation of M 3 R reduces colon tumor formation in vivo. In rodents, azoxymethane (10 mg/kg body weight), an intermediate in the metabolism of 1,2-dimethylhydrazine to the alkylating ion methyldiazonium, is a colorectal-specific procarcinogen (14) . Azoxymethane-induced rodent tumors mimic human colon cancer; most lesions arise in the colon, form grossly visible exophytic polypoid or plaque-like tumors, and have a microscopic appearance similar to that of human adenomas and adenocarcinomas. Molecular changes in azoxymethane-induced tumors, including h-catenin and p53 mutations, also mimic those in human colon cancer (15, 16) . We used the azoxymethane colon cancer model in M 3 R-deficient mice to determine whether M 3 R expression is required for azoxymethane-induced cell proliferation and neoplasia (14) . As reported herein, our findings strongly support the hypothesis that M 3 R plays a key role in colon epithelial cell proliferation and neoplasia.
Materials and Methods
Animals. The generation of M 3 R À/À and wild type (WT) mice of the same mixed genetic background (129S6/SvEvTac Â CF1; 50%/50%) has been described previously (17) . For all experiments, male mice were used. Mice were housed under identical conditions in a pathogen-free room, had free access to commercial rodent chow and water, and were allowed to acclimatize in the vivarium for 2 wk before initiating treatments. Mice were weighed weekly. These studies were approved by the University of Maryland, Baltimore Institutional Animal Care and Use Committee. In situ hybridization. As described previously (18) , digoxigenin-labeled antisense RNA probes were prepared from riboprobe plasmids containing M 1 R and M 3 R inserts. M 1 R riboprobe, synthesized from a 0.28-kb KpnI-SacI genomic fragment cloned into a pBluescript vector, corresponds to the M 1 R sequence lacking in the genome of M 1 R À/À mice. M 3 R riboprobe, synthesized from a 1.6-kb XbaI-Sse8337I genomic fragment, corresponds to M 3 R sequence absent in the genome of M 3 R À/À mice. M 1 R and M 3 R riboprobes were digested with KpnI and NotI, respectively. After purification of linearized plasmids, in vitro transcriptions for M 1 R and M 3 R RNA probes, 280 bp and 1.6 kb in length, respectively, were performed using the Digoxigenin RNA labeling kit (Roche Applied Sciences) with T7 and T3 RNA polymerases, respectively. The length of M 3 R digoxigeninlabeled RNA was shortened by alkaline hydrolysis to f300 bp. The yield of transcripts was estimated using dot blots with control digoxigenin-labeled RNA (Roche Applied Science). Azoxymethane treatment. For the initial 6 wk of treatment, 48 animals received weekly i.p. azoxymethane (Midwest Research Institute; 10 mg/kg body weight; 22 WT and M 3 R À/À 16 mice) or an equal volume of vehicle (PBS; 10 WT mice). To determine tumor incidence, mice were observed for evidence of tumor formation (e.g., anal bleeding) and euthanized at 20 wk. Colon length was measured, segments opened longitudinally, and placed flat on microscope slides. Tumors were identified by visual inspection and photographed using a dissecting microscope (Nikon SMZ1500). Tumor size was measured using calipers and confirmed using Nikon Image-Pro software. Tumor volume was calculated using the equation: volume = 1/2 (length Â width 2 ; ref. 19 ). Histologic analysis. Adenomas and adenocarcinomas were defined according to consensus recommendations (Mouse Models of Human Cancers Consortium; ref. 14). Tumor number was counted in the colon from each mouse. Tumors were photographed, resected, and bisected. Tissues were fixed in 4% paraformaldehyde and paraffin embedded. Fivemicrometer sections were stained with H&E and examined using a Nikon Eclipse 80i microscope. Investigators, who were masked to mouse genotype and treatment, performed gross and microscopic tumor counts, and determined tumor size.
Immunohistologic analysis. Two hours before euthanasia, mice received i.p. injection of BrdUrd (Sigma-Aldrich; 50 mg/kg) to label S-phase cells, a marker of proliferation. BrdUrd labeling was determined after immunostaining with anti-BrdUrd antibody (BD Bioscience) by counting BrdUrd-positive nuclei in 1,000 cells (data expressed as percentage of total cells that were BrdUrd positive). As a marker of apoptosis, we used immunostaining with anti-activated caspase-3 antibody (Cell Signaling Technology; ref. 20) . Only complete crypts were evaluated, and investigators were masked to treatment group. For analysis of both BrdUrd and activated caspase-3 staining, only tissue from the distal half of the colon was examined.
Statistical analysis. Based on distribution of the data, Student's unpaired t test (normally distributed data) or the Mann-Whitney U test (nonparametric data) were used to determine significance. A one-way ANOVA with Tukey HSD test was performed to compare three or more groups. Nominal data were analyzed using m 2 with Fisher's exact test. P values of <0.05 were considered significant. Statistical analysis was performed using StatView (SAS, version 5.0.1). for a total of 6 doses each (Fig. 1C) . Animals were euthanized at 20 weeks to measure tumor number and size, and markers of proliferation and apoptosis (Fig. 1C) . As reported previously (17), at baseline, M 3 R À/À weighed less than WT mice (20.7 grams F 0.5 grams versus 28.3 grams F 0.5 grams; mean F SE; P < 0.001).
Over the course of the 20-week study, WT mice treated with azoxymethane gained less weight than WT mice treated with PBS (33.4 grams F 1.0 grams versus 38.7 grams F 0.6 grams at 20 weeks; P < 0.01; Fig. 1D ). Whereas animals treated with PBS gained weight progressively over the 20-week study, animals treated with azoxymethane did not gain weight during the initial 6 weeks but gained weight once the series of azoxymethane injections was completed (Fig. 1D) . Moreover, although both groups gained weight, azoxymethane-treated WT mice persistently weighed f16% more than M 3 R À/À mice (33.4 grams F 1.0 grams versus 27.9 F 0.5 grams at week 20; P < 0.001; Fig. 1D ). Colons were modestly, but significantly, shorter in M 3 R À/À compared with WT mice (10.7 cm F 0.2 cm versus 11.6 cm F 0.2 cm for M 3 R À/À compared with WT mice treated with azoxymethane; P = 0.002). Before euthanasia, no mice developed rectal bleeding or other clinical evidence of colon tumor formation.
As a marker of cell proliferation, BrdUrd (50 mg/kg) was administered by i.p. injection 2 hours before euthanasia. Figure 2A shows representative micrographs of BrdUrd incorporation in colon mucosa from PBS-treated WT, and azoxymethane-treated WT and M 3 R À/À mice. Azoxymethane treatment induced BrdUrd incorporation in normal colon crypts ( Fig. 2A) . A 5-fold increase in BrdUrd-positive epithelial cells was detected in tissue from azoxymethane-treated WT mice and this was reduced in M 3 R À/À animals ( Fig. 2A and B) . Figure 2B shows an f70% reduction in BrdUrd-positive cells in tissue from M 3 R À/À compared with WT mice (7.2% F 0.9% versus 16.6% F 4.0%; P < 0.05). Clearly, azoxymethane treatment stimulates proliferation of normal colon epithelial cells and this effect is attenuated in M 3 R-deficient mice (Fig. 2B) .
As a marker of apoptosis, sections of colon mucosa from PBStreated WT, and azoxymethane-treated WT and M 3 R À/À mice were examined for activated caspase-3 immunostaining (representative micrographs shown in Fig. 2C ). As depicted in Fig. 2D , the number of apoptotic cells in the three treatment groups was an order of magnitude lower than observed with BrdUrd staining. There was no significant difference in the number of apoptotic cells between groups (P > 0.05). These findings indicate that azoxymethane primarily stimulates epithelial cell proliferation and that genetic ablation of M 3 R reduces cell proliferation with no appreciable effect on apoptosis.
Representative colon sections from azoxymethane-treated animals shown in Fig. 3A indicate reduced tumor number in azoxymethane-treated M 3 R À/À compared with WT mice. At 20 weeks, no colon tumors were observed in WT mice that had not been treated with azoxymethane. Likewise, colon tumors were not observed in M 3 R À/À mice that were not treated with azoxymethane (data not shown). As illustrated in Fig. 3B , WT mice treated with azoxymethane had 5.3 F 0.5 tumors per colon, whereas M 3 R À/À mice had 3.2 F 0.3 tumors per colon; a 40% reduction (P < 0.05). In both WT and M 3 R-deficient mice, all tumors were in the distal half of the colon. Tumor volume was reduced by 60% in M 3 R À/À compared with WT mice (8.1 mm 3 F 1.5 mm 3 versus 20.3 mm 3 F 4.1 mm 3 ; P < 0.05; Fig. 3C ). These findings provide strong evidence that M 3 R gene ablation decreases both colon tumor number and size.
Azoxymethane-induced colon tumors mimicked the gross (Fig. 4A) and microscopic (Fig. 4B ) appearance of human adenomas and adenocarcinomas. Tumors observed in azoxymethanetreated mice included adenomas (Fig. 4B, left) , well-differentiated adenocarcinomas (data not shown), and poorly differentiated À/À compared with WT mice treated with azoxymethane (mean F SE; P < 0.05, Mann-Whitney U test). n, number of mice per treatment group. C, reduced tumor volume in M 3 R À/À compared with WT mice (mean F SE; P < 0.05, Mann-Whitney U test). Columns, mean tumor number per mouse colon; bars, SE. n, number of mice per treatment group. adenocarcinomas (Fig. 4B, middle and right) . To determine the relative number of adenomas and adenocarcinomas, H&E-stained colon sections were reviewed by a pathologist masked to treatment group (22 WT and 16 M 3 R À/À mice treated with azoxymethane).
This analysis revealed that, compared with WT, fewer M 3 R À/À mice had adenomas (6% versus 36%; P = 0.05) and M 3 R À/À mice had fewer adenocarcinomas per mouse (0.6 F 0.1 versus 1.7 F 0.4; P < 0.05; Fig. 4C ). Eleven of 22 WT but no M 3 R À/À mice had multiple adenocarcinomas (P < 0.001). Collectively, these findings indicate that in this murine model of colon cancer, M 3 R-deficiency attenuates the overall number of colon tumors and, more specifically, the number of adenomas and adenocarcinomas.
Discussion
In the United States, colon cancer is a common disease that kills f50,000 people each year. 4 Prevention and early detection by screening, with endoscopic removal of colon adenomas, is effective. However, advanced, nonresectable lesions do not respond well to chemotherapy or radiation. Hence, targeting growth factors and growth factor receptors (e.g., M 3 R) remains an important therapeutic strategy. The present study was designed to evaluate the role of M 3 R in colon neoplasia and to determine whether M 3 R is a potential target for colon cancer treatment.
Using a well-established in vivo model of colon neoplasia and M 3 R-null mice, we provide strong evidence that M 3 R, which are commonly expressed in human colon cancer (7), play a key role in colon neoplasia. In both gross and microscopic appearance, colon tumors in azoxymethane-treated animals mimicked human disease (Fig. 4) . Our findings reveal that in azoxymethane-treated mice, genetic ablation of M 3 R attenuates epithelial cell proliferation, and the number of adenomas and adenocarcinomas per mouse colon (65% reduction in the number of adenocarcinomas per colon). Whereas 50% of azoxymethane-treated WT animals had multiple adenocarcinomas per colon, this was not the case with any M 3 Rdeficient animal. Moreover, in M 3 R-deficient mice, the overall colon tumor volume was reduced by 60% compared with that in WT animals. In the colon, potential muscarinic receptor agonists include acetylcholine that is released by enteric neurons or produced by colon cancer cells as autocrine growth factors. 5 Bile acids that are reported to increase colon cancer risk also interact functionally with M 3 R (11-13). Collectively, these observations suggest that M 3 R may play a role in both tumor initiation and promotion; that is, both the number and size of tumors was reduced in M 3 R-deficient animals. Hence, in addition to being a growth factor receptor, M 3 R may play an important role in initiation of colon neoplasia.
In general, treatment with azoxymethane stimulated a robust increase in epithelial cell proliferation ( Fig. 2A and B) . In contrast, there was little apoptosis in colon sections obtained from animals in any treatment group (Fig. 2C and D) . Neither treatment with azoxymethane nor ablation of M 3 R affected epithelial cell apoptosis as measured by the appearance of activated caspase-3. Therefore, Figure 4 . Azoxymethane-induced tumors mimic human adenomas and adenocarcinomas, and are reduced in M 3 R-deficient mice. A, photograph of two representative adenocarcinomas in the distal colon of an azoxymethane-treated WT mouse. B, representative H&E-stained microscopic images of adenoma and adenocarcinoma in azoxymethane-treated WT mice. Left, adenoma (magnification, Â20). Middle, poorly differentiated adenocarcinoma (magnification, Â20). Right, higher magnification of indicated area of adenocarcinoma (magnification, Â40). *, luminal surface. Green arrowheads, muscularis mucosa. Black arrows, poorly formed glands. C, number of adenomas and adenocarcinomas per mouse colon are reduced in M 3 R-deficient mice. Columns, mean number of adenomas and adenocarcinomas per mouse colon; bars, SE. n, number of mice per treatment group. Unpaired Student's t test.
the role of M 3 R in promoting colon neoplasia seems to depend primarily, if not solely, on proproliferative signaling. This observation is consistent with our in vitro observations in human colon cancer cells that post-M 3 R/EGFR signaling is mediated primarily by the proproliferative ERK pathway and that blocking ERK signaling abolishes M 3 R-agonist-induced cell proliferation (8, (11) (12) (13) .
From the present data, we cannot comment on the role that coexpression of M 1 R and M 3 R in colon epithelial cells plays in colon neoplasia. Previous work indicates that expression of M 1 R does not increase in M 3 R-deficient mice, at least not in those tissues studied (17) . Because M 1 R and M 3 R have a similar G protein coupling profile (2, 3) , it is possible that M 1 R have a similar functional role as M 3 R in colon epithelial cells (18) . This issue can be addressed in future studies by using mice that are deficient in both muscarinic receptor subtypes (18) .
Finally, our findings have potentially important implications regarding reducing expression or activation of M 3 R to prevent or treat colon cancer in humans. Nonetheless, practical translation to clinical trials of the observations presented herein requires demonstration that targeting M 3 R and/or downstream signaling with chemical inhibitors mimics genetic ablation of M 3 R, thereby attenuating colon neoplasia.
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